News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Synchroneuron Announces First Patient Dosed In Phase 2 Tardive Dyskinesia Clinical Trial


2/25/2014 9:37:50 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WALTHAM, Mass.--(BUSINESS WIRE)--Synchroneuron Inc., a biopharmaceutical company engaged in developing new therapies to treat tardive dyskinesia (TD) and other neuropsychiatric disorders, today announced that the first patient has been dosed in a Phase 2, multi-center, randomized, double-blind, placebo-controlled trial evaluating the efficacy, safety and pharmacokinetic behavior of orally-administered SNC-102, a new formulation of acamprosate calcium.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES